Brief: Actinium Highlights Survival Data In Relapsed/Refractory AML Patients
12/12/2022 14:17
Dec 12 (Reuters) - Actinium Pharmaceuticals Inc
ATNM.A :
* ACTINIUM HIGHLIGHTS SURVIVAL DATA IN RELAPSED/REFRACTORY
AML
PATIENTS WITH PRIOR VENETOCLAX TREATMENT AND/OR WITH A TP53
MUTATION FROM THE ACTIMAB-A CLAG-M COMBINATION TRIAL ORAL
PRESENTATION AT ASH
* ACTINIUM PHARMACEUTICALS INC - ACTIMAB-A + CLAG-M WAS WELL
TOLERATED WITH A MANAGEABLE SAFETY PROFILE
* ACTINIUM PHARMACEUTICALS INC - 59% 1-YEAR OVERALL SURVIVAL
AND
32% 2-YEAR OVERALL SURVIVAL IN PATIENTS WITH PRIOR VENETOCLAX
TREATMENT
* ACTINIUM PHARMACEUTICALS INC - 52% 1-YEAR OVERALL SURVIVAL
AND
19% 2-YEAR OVERALL SURVIVAL IN PATIENTS WITH A TP53 MUTATION
* ACTINIUM PHARMACEUTICALS INC - 75% MEASURABLE RESIDUAL
DISEASE
NEGATIVITY ACHIEVED IN HEAVILY PRETREATED, HIGH-RISK RELAPSED OR
REFRACTORY PATIENTS
Source text for Eikon: ID:nPn1vfv07a
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities